Upload
haduong
View
214
Download
0
Embed Size (px)
Citation preview
Creating value through responsible businessCorporate Citizenship at Novartis
John B. KetchumRegion Head, Novartis Oncology Asia PacificJakarta, October 13, 2008
2 Novartis Corporate Citizenship
Novartis aspires to become the world’s most respected healthcare company
Our purposeCaring and curing is our purpose
Our aspirationOur aspiration is to be the world’s most respected healthcare company
Our strategyWe have the best portfolio to meet the healthcare needs of patients and society
3 Novartis Corporate Citizenship
Novartis best positioned to meet changing healthcare needs
Our medicine-based portfolio provides:• Innovative pharmaceuticals• High-quality, low-cost generics• Preventive vaccines• Self-medication (OTC) brands
Only company with leadership positions in both patented and generic pharmaceuticalsServing patients, physicians and payors
4 Novartis Corporate Citizenship
Medicines: Socially Sensitive Products
Medicine development is risky, long, and expensive: • Only 10% of medicines that start development get to market – after
an average of 15 years and > USD 800 million invested
Therefore successful medicines can be costly during the first years on the market – the period of brand exclusivity
But can deliver extremely high value in patient well being
This creates a powerful dynamic that stimulates spirited debate and close scrutiny of pharma companies
As a medicines based company, Novartis accepts a responsibility to behave as a good corporate citizen
5 Novartis Corporate Citizenship
What does good corporate citizenship mean?
Corporate citizenship is about creating value through responsible businessCorporate citizenship principles guide responsible behavior:• Activities in which we engage and how we conduct them
Citizenship is integral to how we develop, manufacture, market and distribute our productsProvides benefits to society beyond economic success
6 Novartis Corporate Citizenship
Corporate citizenship is the right thing to do and makes good business sense
Corporate citizenship is integral to how we operate
Drivebusiness success
STRENGTHENREPUTATION
Being a trustworthy and strong partner Maintaining “license to innovate, operate and grow”
IMPROVE ACCESS TO MEDICINE
BUILD AN ETHICAL CULTURE
Building a value-based corporate cultureAttracting and growing talent
SHAPE NEW MARKETS
Attracting investorsMitigating risks and capitalizing on new opportunities
Gaining recognition asa company committed to improving access to medicine
7 Novartis Corporate Citizenship
The four pillars of corporate citizenship at Novartis
People and communities
Diversity & inclusionLiving wageHealth & safety Community involvementEmergency aid
Environment
Risk prevention & managementResource management
Patients
AccessResearchClinical trialsDialogue
We want to discover, develop and successfully market innovative products to cure and prevent diseases, to ease suffering and to enhance the quality of life. We also want to provide a shareholder return that reflects outstanding performance and to adequately reward those who invest ideas and
work in our company.
Businessconduct
Integrity & ComplianceMarketing practicesThird-party managementIntegrity Line
8 Novartis Corporate Citizenship
“We believe that each sphere of society – from government and charitable organizations, to medical
professionals and business – has a role to play in support of the right to health.”
Commitment to patients
Position on the Right to HealthExecutive Committee of Novartis (2004)
9 Novartis Corporate Citizenship
Discovering new vaccines and drugs against neglected diseases
Novartis Institute for Tropical Diseases (NITD) established in 2003 in SingaporePartnership between Novartis and the Singapore Economic Development BoardResearch into dengue fever, malaria and tuberculosisTreatments to be made available without profit to patients in developing countriesNovartis Vaccines Institute for Global Health (NVGH) launched in 2008
10 Novartis Corporate Citizenship
NFSD improving access to healthcare for the poor and eradicating diseases
More than 25 years of commitment from Novartis Foundation for Sustainable Development (NFSD) to eradicating poverty and neglected diseases Three main areas of focus:• Think-tank • Stakeholder dialogue and networking• Grassroots projects
11 Novartis Corporate Citizenship
Novartis working to eliminate tuberculosis
Novartis DOTS1 combination of medicines including Rimactane (rifampicin)DOTS is the recommended therapy of WHO500,000 free treatments provided from 2003-2008Collaboration between NITD and Global TB Alliance to simplify treatment
1 Directly Observed Treatment, Short-course
Tuberculosis (TB) is an airborne infectious disease TB kills 8 000 people each day, two million each year, making it the world’s top killer diseaseSomeone in the world infected with TB every second (6 to 8 million new cases annually)
About TB
12 Novartis Corporate Citizenship
Novartis fighting to eliminate leprosy
Free treatment provided to patients through WHO Novartis developed two of the three products used in multi-drug therapy to treat leprosyMore than 14 million patients cured since 1985• 4.3 million patients helped
in Novartis-WHO collaborationDrug donations of USD 40 millionLeprosy now eliminated on country level in all but four countries• Special efforts needed to eliminate
on sub-national levels
Leprosy is an infectious disease caused by bacteriaMore than one million people still live with permanent disabilities caused by leprosyMulti-drug therapy recommended by WHO developed in 1980s
About leprosy
13 Novartis Corporate Citizenship
Rolling back malaria with Coartem
Coartem the treatment of choice against malaria with cure rates of up to 96%Coartem cost in 2006 cut to USD 1.00 per treatment thanks to Novartis subsidyNovartis has annual capacity to make 100 million treatments66 million treatments delivered in 2007New pediatric formulation under development (2008)
Malaria ranks No. 3 among infectious-disease killers A child under age 5 dies every 30 seconds from malaria in Africa1 million people die every year from malaria, with 300-500 million new cases annually
About malaria
14 Novartis Corporate Citizenship
Ensuring access to all through the Glivec International Patient Assistance Program
Started in 2001, GIPAP provides Glivec at no cost for eligible patients with CML and GIST
Global network of more than 1,000 GIPAP physicians and 429 qualified treatment centers
Novartis works with governments, NGOs, physicians as well as local and global healthcare organizations to expand GIPAP
More than 33,000 patients reached in more than 80 countries since 2001
Total donation of USD 534 million in 2007
Glivec inhibits the principal causes of two forms of cancer – chronic myeloid leukemia (CML) and Kit (CD117) positive gastrointestinal stromal tumor (GIST)
CML and GIST affect 1 to 2 people per 100,000 annually
Facts
Patients
15 Novartis Corporate Citizenship
Exploring innovative partnerships
As emerging countries evolve, Novartis explores new ways to provide access to a broader group of patients through innovative public-private partnerships
Glivec Global Access Programs today include a range of flexible models in which Novartis partners with governments, charities and other payors
Novartis also works with NGOs, physicians and other healthcare providers to customize patient access models to achieve our common goal…
…the best cancer care possible for the most patients
Patients
16 Novartis Corporate Citizenship
GIPAP in Indonesia: A local example of good citizenship
Has helped more than 300 patients since being established in 2003
Dispenses IDR 1.7 Billion worth of Glivec free to patients each month
Commercial (paid) sales of Glivec in Indonesia are <IDR 0.5 Billion per month
Patients
17 Novartis Corporate Citizenship
GIPAP Indonesia is a partnership for the benefit of patients
Stakeholders include:• Hematologists and Oncologists
• Indonesian Cancer Foundation DKI Jakarta Province
• TMF
• Novartis Oncology
Centers provide access in several geographies• Jakarta – Cipto Mangunkusumo Hospital
• Bandung – Hasan Sadikin Hospital
• Semarang – Kariadi Hospital
• Surabaya – Sutomo Hospital
• Jogja – Sarjito Hospital
Patients
18 Novartis Corporate Citizenship
1 World Health Organization
Novartis is a leader in drug access programs….
Leprosy (free to WHO1):Over 4 million patients treated since 2000
Malaria / Coartem: 66 million treatments delivered in 2007
Tuberculosis (with WHO): 500,000 free treatments provided over 5 years
Glivec Patient Assistance Program: Free therapy to 33,000 people in 80 countries
Novartis Institute for Tropical Diseases:Singapore-based research initiative
Access programs worth USD 937 million reached 66 million patients in 2007
Patients
19 Novartis Corporate Citizenship
“Corporate citizenship implies many things that add up to responsible behavior of a
company within society. In the end, doing the right thing also
makes business sense.”
…Because we believe that doing the right thing makes business sense
Daniel Vasella, MDChairman and Chief Executive Officer
Novartis